Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02899195
Title Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PrECOG, LLC.

malignant pleural mesothelioma


Cisplatin + Durvalumab + Pemetrexed Disodium


Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.